Clinical and Pathologic Studies in Non-Hodgkin’s Lymphoma Patients Receiving Antibody Treatment

Overview

To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.

Full Title of Study: “Le20: Clinical and Pathologic Studies in Non-Hodgkin’s Lymphoma Patients Receiving Antibody Treatment”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2007

Interventions

  • Drug: Rituximab
  • Drug: Epratuzumab

Clinical Trial Outcome Measures

Primary Measures

  • To characterize the molecular and cell biology of the tumor cells in lymphoma.
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Stanford University
  • Collaborator
    • Amgen
  • Provider of Information About this Clinical Study
    • Wen-Kai Weng, Stanford University School of Medicine
  • Overall Official(s)
    • Wen-Kai Weng, Principal Investigator, Stanford University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.